Molecular diagnostics company, Blue Earth Diagnostics and GE Healthcare have signed an agreement to manufacture the Positron Emission Tomography (PET) imaging product Axumin® in the UK.
The imaging product Axumin was developed to target the increased amino acid transport that occurs in many cancers, including prostate cancer – image courtesy of Pixabay Following receipt of marketing authorization for Axumin from the European Commission in May 2017, Blue Earth Diagnostics is working to build a network of authorized…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
